A Multi-centre Observational Study on Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients Under Gefitinib Treatment
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Oct 2016 Status changed from active, no longer recruiting to recruiting.
- 24 Jun 2016 New trial record